Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences develops neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its news commonly centers on EB-003, a lead candidate from the EVM301 Series designed to promote neuroplasticity without hallucinogenic effects and to modulate 5-HT2A and 5-HT1B receptors. Company updates also discuss preclinical models tied to PTSD, depression, anxiety and related neuropsychiatric conditions.
Recurring announcements include intellectual-property activity for the EVM301 and EVM401 Series, trademark registrations, corporate and financial results, and capital actions involving common stock, pre-funded warrants and other warrants. Enveric also reports business-development and conference activity around non-hallucinogenic and psychedelic-inspired therapeutic approaches.
Enveric Biosciences (NASDAQ: ENVB) has initiated IND-enabling genotoxicity studies for its lead neuroplastogen candidate, EB-003, a small-molecule therapeutic for psychiatric and neurological disorders.
The GLP studies, following ICH S2(R1) guidelines, include Ames and Micronucleus assays and support a potential future Phase 1 first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) reported positive preclinical in vitro phototoxicity results for lead neuroplastogen EB-003. Testing showed no photoreactive potential, reducing safety concerns for chronic treatment of neuropsychiatric disorders, including depression, anxiety and PTSD. This marks a further preclinical safety milestone as Enveric prepares for first-in-human Phase 1 trials.
Enveric Biosciences (NASDAQ: ENVB) reported first quarter 2026 results and a corporate update. Net loss attributable to stockholders was $1.6 million (loss/share $1.08) versus $2.2 million (loss/share $14.58) a year earlier, with $4.9 million cash at March 31, 2026.
The company advanced lead candidate EB-003 through IND-enabling studies and reported preclinical data showing dual Gq and β-arrestin 5-HT2A signaling and reduced conditioned fear in a PTSD model. Enveric strengthened its IP portfolio, noted withdrawal of a Post-Grant Review petition relating to patents tied to bretisilocin (GM-2505), and enhanced EVM301 coverage.
Enveric raised $2.8 million in Q1 offerings, followed by a private placement of up to $13.9 million (including $5 million upfront) and $1.5 million from warrant exercises, bringing cash to about $10.3 million as of May 15, 2026, which it believes funds operations into Q1 FY 2027.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of US Patent No. 12,605,361 for methods of treating psychiatric disorders using its EVM301 Series carboxylated psilocybin derivatives. The April 21, 2026 patent broadens protection for tryptamine-based drug candidates and supports development of lead candidate EB003 targeting depression and anxiety.
Enveric Biosciences (NASDAQ: ENVB) highlighted preclinical results for EB-003, a dual 5-HT2A/5-HT1B modulator. A single dose significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05), indicating a rapid reduction in conditioned fear in a validated PTSD model.
The company positioned EB-003 as a next-generation neuroplastogen targeting neuroplasticity and mood signaling pathways as interest in psychedelic-inspired therapies grows.
Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) appointed Joseph Tucker, Ph.D., CEO of Enveric Biosciences (NASDAQ: ENVB), to its Board of Directors on April 28, 2026. The appointment follows Lakewood-Amedex's recent Nasdaq direct listing and is positioned to strengthen governance and strategic capabilities as the company advances its Bisphosphocin® program, including lead candidate Nu-3 for infected diabetic foot ulcers.
Dr. Tucker brings more than two decades of biotech leadership, experience with public listings, M&A, and capital raises, including having raised over $100 million and advancing Enveric's EB-003 toward an anticipated first-in-human trial.
Enveric Biosciences (NASDAQ: ENVB) said CEO Joseph Tucker, Ph.D., will join a panel at Needham’s Virtual Psychedelics Forum on Monday, April 27, 1:00 PM - 2:00 PM ET.
The panel topic is "Beyond TRD: Non-Hallucinogens and New Indications". Management will hold one-on-one investor and partner meetings to review clinical strategy and anticipated milestones. Registration is available online.
Enveric Biosciences (NASDAQ: ENVB) closed a private placement priced at-the-market on April 17, 2026, raising approximately $5.0 million in gross proceeds from the sale of 2,222,223 shares (or pre-funded warrants) and accompanying warrants at $2.25 per share.
The offering includes Series I warrants and short-term Series J warrants to buy up to 2,222,223 shares each at a $2.00 exercise price, potentially providing an additional $8.9 million if fully exercised; the company intends to use net proceeds for product development, working capital and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced a private placement priced at-the-market to raise approximately $5.0 million upfront and up to $8.9 million additional if warrants are fully exercised. The offering includes 2,222,223 shares and Series I and J warrants exercisable at $2.00.
Closing expected on or about April 17, 2026; H.C. Wainwright is placement agent. Net proceeds to fund product development, working capital, and general corporate purposes.
Enveric Biosciences (NASDAQ: ENVB) announced that U.S. Patent No. 12,577,232 was issued on March 17, 2026, covering its EVM301 Series of N-heterocycle substituted tryptamine derivatives.
The patent claims chemical compounds, pharmaceutical formulations, and methods for treating brain neurological disorders and expands coverage alongside U.S. Patent No. 12,338,231. Enveric cites lead candidate EB-003 and says it is progressing toward an IND submission and a first-in-human Phase 1 trial. The company reports a patent estate of 27 issued U.S. patents and approximately 60 pending national and international applications.